Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab
Yusuke Morita, Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Toshimitsu Ichimaru, Lingaku Lee, Yusuke Niina, Terumasa Hisano, Masayuki Furukawa, Keishi Sugimachi, Masatake Tanaka, Ilyas Sahin · 2025
Read Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab by Yusuke Morita, Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Toshimitsu Ichimaru, Lingaku Lee, Yusuke Niina, Terumasa Hisano, Masayuki Furukawa, Keishi Sugimachi, Masatake Tanaka, Ilyas Sahin (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12730319.txt.
Description
Yusuke Morita and co-authors compare two three-drug cocktails for advanced bile duct cancer and find the cheaper one holding patients longer. The standard pairs two chemotherapy drugs with an immunotherapy; the challenger swaps the immunotherapy for S-1, an oral fluoropyrimidine long used in Japan. Their 2025 prospective observational study follows fifty-two patients on the challenger and forty-four on the standard.
Survival overall did not differ significantly, at about nineteen months against twelve in the raw numbers. Time without the cancer progressing, though, favored the challenger clearly, ten months against six, and tumor shrinkage was more than twice as common. A matched analysis balanced the groups and re-checked the findings, and drug costs were tallied to the end of treatment. The authors make an unfashionable point with data: in this cancer, the imported immunotherapy premium bought no survival its cheaper rival lacked.
Catalog record
| CREATOR | Yusuke Morita, Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Toshimitsu Ichimaru, Lingaku Lee, Yusuke Niina, Terumasa Hisano, Masayuki Furukawa, Keishi Sugimachi, Masatake Tanaka, Ilyas Sahin |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |